Close menu

April 19th, 2023 | 07:30 CEST

Morphosys, Defence Therapeutics, Moderna - The takeover wave keeps rolling

  • Biotechnology
  • Pharma
  • Cancer
Photo credits:

The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions to unmet medical needs. The most recent example is Pfizer's acquisition of Seagen for USD 43 billion. With Big Pharma sitting on filled coffers, this is likely to be just the beginning.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: MORPHOSYS AG O.N. | DE0006632003 , DEFENCE THERAPEUTICS INC | CA24463V1013 , MODERNA INC. DL-_0001 | US60770K1079

Table of contents:

    Defence Therapeutics - Takes landmark step

    The goal of the Canadian biotech company is to further improve mRNA vaccines through its patented ACCUM™ technology. As a result, comparative studies have been launched, testing a "naked" mRNA vaccine against a combined mRNA vaccine with ACCUM™. The study has a duration of 6 weeks, and the team led by Defence Therapeutics CEO, Sébastian Plouffe, expects results soon. "These in-vivo tests are very important for our strategic growth as they will show how the ACCUM™ technology can be adapted to synergize with mRNA vaccines."

    If the trial is successful, ACCUM™ technology will likely become a component of mRNA research in the future. In addition to developing the Company's own vaccine, Accum could thus be applied to third-party projects.

    Moreover, Defence Therapeutics, with a stock market value of CAD 158.19 million, could become an attractive takeover candidate. The wave of acquisitions in the biotechnology sector has been happening for months. Most recently, the pharmaceutical giant Pfizer acquired Seagen, a company that can be classified in Defence Therapeutics' peer group. The purchase price amounted to USD 43 billion. The focus of the US company Seagen is to fight cancer through the use of antibody-drug conjugates.

    Moderna - Hard hit

    The shares of the pharmaceutical company slumped by more than 8% at the start of the week. As a result, the share price is moving into dangerous territory at USD 143.97. Because if the support area at USD 116 falls, there is a threat of a rapid sell-off in the direction of the 2020 high at USD 94.85.

    The sharp correction was due to the publication of data from a midstage combination trial involving Moderna's mRNA cancer vaccine mRNA-4157 (V940) and Merck's Keytruda, specifically for melanoma or stage 3 and 4 skin cancer. The companies tested a combination of Merck's Keytruda and their personalized cancer vaccine in melanoma patients after surgery. After one year, more than 83% of patients had neither relapsed nor died. After 18 months, when almost 79% of the patients were still alive and cancer-free, the responses intensified. The results surpassed those of the non-combined drug Keytruda.

    Still, the path forward for Moderna and Merck probably does not include accelerated approval, analysts said. The trial was only conducted with 157 patients. Moderna and Merck plan to start a Phase III trial with the personalized cancer vaccine this summer. The vaccine prepares the immune system to recognize the patient's own tumour cells. If it returns, this could give the immune system a chance to fight the cancer.

    Morphosys - Looking for the bottom

    The biotech company from Planegg near Munich had already experienced a sharp sell-off in the past two years. Since its peak on January 13, 2020, when it reached a high of EUR 146.30, the stock has lost over 90% of its value. Since the low of EUR 11.80 at the end of December last year, however, the share has initiated a significant countermovement and is currently trading at EUR 19.13. Once the high for the year at EUR 19.77 is overcome, a further rise, initially to the EUR 24.63 range, would be possible.

    The biotech company received a tailwind from positive study results, which were published together with the distribution partner Incyte. According to the Company, the data from the five-year follow-up period of the Phase II L-MIND trial show "a prolonged and durable response to Monjuvi" in adult patients with relapsed or refractory diffuse large B-cell lymphoma. There were no new abnormalities in side effects, he said.

    "Five-year data demonstrating durability of response are of great importance to oncologists when weighing the most appropriate treatment option for a patient. The prolonged and durable response rates observed in the L-MIND study in relapsed or refractory DLBCL patients after five years show that treatment with Monjuvi may potentially cure the disease," says Johannes Düll from the Medical Clinic and Polyclinic of the University Hospital of Würzburg.

    The takeover wave in the biotech sector is rolling. Seagen, represented in the peer group with Defence Therapeutics, was acquired by Pfizer for USD 43 billion. Moderna's study results did not convince analysts. In contrast, Morphosys was able to report positive news with its partner Incyte.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.


    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.